M6P Therapeutics specializes in lysosomes, which are the recycling centers within cells that break down waste materials. Using their proprietary S1S3, they can create therapies to address all ~60 lysosomal storage disorders. They also created a new class of antibodies that can be degraded by virtually any cell in the body by lysosomes.